AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections

Summary

This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection. * Primary endpoint: significant drop in viral load AV2-DM versus placebo * Secondary endpoint:the number of patients with adverse events

Timeline

Start

2012-08

Primary completion

2012-12

Completion

2013-01

Drugs

Indications